Quizartinib, a potent type II FLT3 inhibitor, has shown efficacy in relapsed/refractory FLT3-mutated AML, with notable responses even in FLT3-wild-type disease [11,12]. This evidence concerns the gene FLT3 and acute myeloid leukemia.